[ET Net News Agency, 16 November 2022] IMMUNOTECH-B (06978) rose 11.01% to HK$6.05.
It hits an intra-day high of HK$6.05, and an intra-day low of HK$5.5. The total shares
traded was 2.43 million, with a value of HK$14.1m. The active buy/sell ratio is 55:45,
with net buying turnover of HK$1.23m. GOLDMAN SACHS (ASIA) SEC accounts for greatest net
responsive buying turnover of HK$614,698, with volume weighted average price of HK$5.772.
CHINA INNOVATION MARKET SER accounts for greatest net responsive selling turnover of
HK$844,596, with volume weighted average price of HK$5.829. The stock has risen a combined
22.72% over the past 4 consecutive trading days.
The Hang Seng Index now fell 81 points, or 0.45% to 18,261; the Hang Seng China
Enterprises Index now fell 32 points, or 0.52% to 6,236; the Hang Seng TECH Index now fell
8 points, or 0.21% to 3,805; with an overall turnover of HK$49.31b.
The SSE Composite Index now rose 2 points, or 0.07% to 3,136, with an overall turnover
of RMB134.41b.
The SZSE Component Index now fell 23 points, or 0.21% to 11,327, with an overall
turnover of RMB78.23b.
Basic Information
=================
---------------------------------
Nominal 6.050 % Chg +11.01%
High 6.050 Low 5.500
Shares Tr 2.43m Turnover 14.1m
10-D SMA 5.302 %H.V 93.948
20-D SMA 5.218 VWAP 5.806
50-D SMA 4.477 RSI14 66.124
---------------------------------
Status: Active buy/sell ratio is 55:45, with net buying turnover of HK$1.23m, rising a
combined 22.72% over the past 4 consecutive trading days
Performance of stocks in the same sector or of relevance
========================================================
Stock (Code) Price (HK$) Change (%)
-----------------------------------------------
IMMUNOTECH-B (06978) 6.05 +11.01
INNOVENT BIO (01801) 35.00 +0.29
JXR (01951) 5.50 +0.18
BRII-B (02137) 9.44 +1.94
CLOVER BIO-B (02197) 4.30 +10.26
WUXI BIO (02269) 53.90 -0.19
CANSINOBIO (06185) 109.90 -6.63
SCICLONE PHARMA (06600) 6.89 -2.13
AKESO-B (09926) 33.70 +4.50
KINTOR PHARMA-B (09939) 15.42 +4.90
-----------------------------------------------
(ed)